Proton pump inhibitors (PPIs) and related acid suppression agents prior authorization and quantity limits
Policy governs prior authorization, quantity limits, formulary status, and coverage exceptions for proton pump inhibitors and related products for BCBSMA commercial members under the pharmacy benefit. It applies to commercial lines including HMO/POS, PPO/EPO, Indemnity, Medex with Rx, and Managed Blue for Seniors.
Added new FDA indication to Voquezna and updated formatting and references.
Updated to add Voquezna to the policy.
Updated to add Omeprazole + Syrspend and Konvomep to the policy as non-preferred.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.